<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00627666</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000583220</org_study_id>
    <secondary_id>AMC-UUCM-2003-0207</secondary_id>
    <nct_id>NCT00627666</nct_id>
  </id_info>
  <brief_title>Donor Stem Cell Transplant After Busulfan, Fludarabine, and Antithymocyte Globulin in Treating Patients With Hematological Cancer</brief_title>
  <official_title>Unrelated Donor Hematopoietic Stem Cell Transplantation After Nonmyeloablative Conditioning For Patients With Hematological Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Giving chemotherapy before a donor bone marrow stem cell transplant helps stop the
      growth of cancer cells. Chemotherapy and antithymocyte globulin stop the patient's immune
      system from rejecting the donor's stem cells. The donated stem cells may replace the
      patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor
      effect). Sometimes the transplanted cells from a donor can also make an immune response
      against the body's normal cells. Giving cyclosporine and methotrexate after transplant may
      stop this from happening.

      PURPOSE: This phase II trial is studying how well giving donor stem cell transplant together
      with busulfan, fludarabine, and antithymocyte globulin works in treating patients with
      hematological cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  To investigate whether unrelated donor hematopoietic stem cell transplantation using a
           nonmyeloablative conditioning regimen comprising busulfan, fludarabine phosphate, and
           anti-thymocyte globulin can reduce treatment-related mortality in patients with
           hematologic malignancies.

        -  To investigate whether this regimen can be sufficiently immunosuppressive to enable
           engraftment of HLA-matched unrelated hematopoietic stem cells.

      OUTLINE: This is a multicenter study.

      Prior to receiving the conditioning chemotherapy regimen, all patients with acute leukemia,
      chronic myelogenous leukemia (CML), and high-risk myelodysplastic syndromes (chronic
      myelomonocytic leukemia, atypical CML, and refractory anemia with excess blasts) receive one
      dose of intrathecal (IT) methotrexate. These patients also receive leucovorin calcium IV or
      orally 4 hours after IT methotrexate and every 6 hours for a total of 8 doses.

        -  Nonmyeloablative conditioning regimen: Patients receive fludarabine phosphate IV over 30
           minutes on days -7 to -2, busulfan IV over 3 hours on days -7 to -6, anti-thymocyte
           globulin IV over 4 hours on days -4 to -2.

        -  Allogeneic bone marrow stem cell transplantation (SCT): Patients undergo allogeneic bone
           marrow SCT on day 0.

        -  Graft-versus-host-disease (GVHD) prophylaxis: Patients receive cyclosporine (CSA) IV
           over 2-4 hours every 12 hours starting on day -1 and continuing until day 180 (CSA can
           be given orally every 12 hours once oral medication can be tolerated) and methotrexate
           IV on days 1, 3 , 6 , and 11.

      Once blood counts recover, patients with acute leukemia or CML in blast crisis resume IT
      methotrexate once every 2 weeks for a total of 3 doses. Patients also receive leucovorin
      calcium IV or orally 4 hours after IT methotrexate and then every 6 hours for a total of 8
      doses.

      Patients are followed for at least 10 years after SCT.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2003</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment-related mortality</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Engraftment</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Regimen-related toxicities</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft-versus-host-disease</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Failure-free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>100-day transplant-related mortality</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Myelodysplastic/Myeloproliferative Neoplasms</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>anti-thymocyte globulin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>busulfan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin calcium</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic bone marrow transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic hematopoietic stem cell transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>nonmyeloablative allogeneic hematopoietic stem cell transplantation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of any 1 of the following:

               -  Acute leukemia

               -  Chronic myelogenous leukemia

               -  Myelodysplastic syndromes

          -  Must have an unrelated donor available who is matched for HLA-A and -B by serology and
             for DRB1 by molecular typing

        PATIENT CHARACTERISTICS:

          -  Karnofsky performance status 70-100%

          -  Bilirubin &lt; 3.0 mg/dL

          -  Creatinine &lt; 2.0 mg/dL

          -  AST and ALT &lt; 3 times the upper limit of normal

          -  Not pregnant or nursing

          -  Ejection fraction â‰¥ 45% by MUGA scan or ECHO

          -  No major illness or organ failure

          -  No severe psychiatric disorder or mental deficiency that makes compliance with the
             treatment unlikely and informed consent impossible

        PRIOR CONCURRENT THERAPY:

          -  Not specified
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyoo H. Lee, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asan Medical Center - University of Ulsan College of Medicine</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <results_reference>
    <citation>Lee KH, Choi SJ, Lee JH, Lee JH, Kim DY, Seol M, Lee YS, Kang YA, Jeon M, Yun SC, Joo YD, Lee WS, Kang MJ, Kim H, Park JH, Bae SH, Ryoo HM, Kim MK, Hyun MS. Clinical effect of reduced-intensity conditioning regimen containing antithymocyte globulin for hematopoietic cell transplantation from unrelated-donors. Am J Hematol. 2011 May;86(5):399-405. doi: 10.1002/ajh.21989.</citation>
    <PMID>21523798</PMID>
  </results_reference>
  <verification_date>July 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 29, 2008</study_first_submitted>
  <study_first_submitted_qc>February 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2008</study_first_posted>
  <last_update_submitted>March 25, 2013</last_update_submitted>
  <last_update_submitted_qc>March 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2013</last_update_posted>
  <keyword>adult acute lymphoblastic leukemia in remission</keyword>
  <keyword>recurrent adult acute lymphoblastic leukemia</keyword>
  <keyword>untreated adult acute lymphoblastic leukemia</keyword>
  <keyword>adult acute myeloid leukemia in remission</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>untreated adult acute myeloid leukemia</keyword>
  <keyword>acute lymphocytic leukemia</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>acute undifferentiated leukemia</keyword>
  <keyword>mast cell leukemia</keyword>
  <keyword>accelerated phase chronic myelogenous leukemia</keyword>
  <keyword>blastic phase chronic myelogenous leukemia</keyword>
  <keyword>chronic phase chronic myelogenous leukemia</keyword>
  <keyword>meningeal chronic myelogenous leukemia</keyword>
  <keyword>relapsing chronic myelogenous leukemia</keyword>
  <keyword>chronic myelomonocytic leukemia</keyword>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(15;17)(q22;q12)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>atypical chronic myeloid leukemia, BCR-ABL1 negative</keyword>
  <keyword>myelodysplastic/myeloproliferative neoplasm, unclassifiable</keyword>
  <keyword>refractory anemia with excess blasts in transformation</keyword>
  <keyword>refractory anemia with excess blasts</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

